# Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

> **NCT01732770** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 643 (actual)

## Conditions studied

- Post Menopausal Osteoporosis

## Interventions

- **BIOLOGICAL:** Denosumab
- **DRUG:** Zoledronic Acid
- **DRUG:** Placebo to Denosumab
- **DRUG:** Placebo to Zoledronic Acid

## Key facts

- **NCT ID:** NCT01732770
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-07
- **Primary completion:** 2015-01-07
- **Final completion:** 2015-01-07
- **Target enrollment:** 643 (ACTUAL)
- **Last updated:** 2020-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01732770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01732770, "Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT01732770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*